Breast cancer drug adherence under the microscope: will patients stick with treatment?

NCT ID NCT07531693

Recruiting now Knowledge-focused Sponsor: Institut fuer Frauengesundheit Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study tracks 200 women with high-risk HR+/HER2- early breast cancer to see how many continue taking abemaciclib six months after starting. Researchers will review therapy data from 2023 to 2025. The goal is to understand real-world persistence, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abemaciclib
What this could lead to: If successful, this study could help doctors understand why some patients stop taking abemaciclib early, potentially leading to better support and improved treatment adherence.
What could go wrong: This is an observational study, not a treatment trial. It only looks back at existing data, so it cannot prove what causes patients to stop therapy or improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HR+/HER2- EARLY BREAST CANCER

Contacts and locations

Locations

Department of Obstetrics and Gynaecology, Uniklinikum Erlangen
RECRUITING

Erlangen, Bavaria, 91054, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.